Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | DNM1 | Q05193 | 9/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9513225 | 1.00 | LMNA (0.54) | LMNADNM1ALDH1A1TSHRMEN1 | |
| SCHEMBL14840420 | 1.00 | LMNA (0.54) | LMNADNM1ALDH1A1TSHRMEN1 | |
| SCHEMBL2230600 | 1.00 | LMNA (0.54) | LMNADNM1ALDH1A1TSHRMEN1 | |
| SCHEMBL5870603 | 1.00 | LMNA (0.54) | LMNADNM1ALDH1A1TSHRMEN1 | |
| SCHEMBL25469862 | 1.00 | LMNA (0.54) | LMNADNM1ALDH1A1TSHRMEN1 | |
| SCHEMBL14839987 | 1.00 | LMNA (0.54) | LMNADNM1ALDH1A1TSHRMEN1 | |
| SCHEMBL23586497 | 1.00 | LMNA (0.54) | LMNADNM1ALDH1A1TSHRMEN1 | |
| SCHEMBL14839929 | 1.00 | LMNA (0.54) | LMNADNM1ALDH1A1TSHRMEN1 | |
| SCHEMBL19119422 | 1.00 | LMNA (0.54) | LMNADNM1ALDH1A1TSHRMEN1 | |
| SCHEMBL10460520 | 1.00 | LMNA (0.54) | LMNADNM1ALDH1A1TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1848702-A2 | PRO-FRAGRANCE AND PRO-FLAVORANT COMPOSITIONS | Flexitral, Inc. (US) | 2007-10-31 | — | — | EP | claimed |
| WO-2006085048-A2 | PRO-FRAGRANCE AND PRO-FLAVORANT COMPOSITIONS | FLEXITRAL, INC. (US) | 2006-08-17 | — | — | WO | claimed |
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | DISC MEDICINE, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20200345804-A1 | NOVEL AGENTS TARGETING INHIBITOR OF APOPTOSIS PROTEINS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-11-05 | — | — | US | disclosed |
| US-10660939-B2 | Therapies for obesity, diabetes and related indications | PALATIN TECHNOLOGIES, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-20180153965-A1 | Therapies for Obesity, Diabetes and Related Indications | PALATIN TECHNOLOGIES INC (US) | 2018-06-07 | — | — | US | disclosed |
| US-9891239-B2 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20170143680-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200345804-A1 | NOVEL AGENTS TARGETING INHIBITOR OF APOPTOSIS PROTEINS | XIAP, BIRC2, BIRC5 | LMNA 1297/4885DNM1 1289/4885ALDH1A1 4170/4885 |
| US-10660939-B2 | Therapies for obesity, diabetes and related indications | MC4R, GLP1R, MC3R | LMNA 3903/4885DNM1 2358/4885ALDH1A1 3071/4885 |
| US-20170143680-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, ABCB11 | LMNA 3534/4885DNM1 820/4885ALDH1A1 994/4885 |
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | MMP7, MATR3, SPINT2 | LMNA 1207/4885DNM1 3284/4885ALDH1A1 3877/4885 |
| US-20180153965-A1 | Therapies for Obesity, Diabetes and Related Indications | MC4R, GLP1R, MC3R | LMNA 3903/4885DNM1 2358/4885ALDH1A1 3071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.